Breast cancer
Drug research and approvals for breast cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 2,449 studies of breast cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 267 drug trials for it since 2013, FDA has 7 approved and 6 open orphan designations naming it, and the EU has 50 authorised medicines for it.
- Recruiting worldwide: 2,449
- Trials authorized in Canada: 267
- FDA orphan approvals: 7
- EU medicines: 50
- STIL Block Versus Paravertebral Block for Pain Relief After Modified Radical MastectomyNCT07950982 · Not applicable · National Cancer Institute, Egypt · starts Nov 10, 2026
- Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN)NCT07947472 · Not reported · Centre Hospitalier Intercommunal Creteil · starts Nov 9, 2026
- Neoadjuvant Trastuzumab Rezetecan Plus Toripalimab and Endocrine Therapy in HR-Positive HER2-Low Breast CancerNCT07949695 · Phase 2 · Tianjin Medical University Cancer Institute and Hospital · starts Nov 1, 2026
- Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer PatientsNCT07933653 · Not applicable · First Affiliated Hospital of Guangxi Medical University · starts Nov 12, 2026
- Gryrotonic Training in Behcet-diseased Elders With Breast CancerNCT07929116 · Not applicable · Cairo University · starts Nov 30, 2026
- Pectoral Nerve Block Versus Serratus Posterior Superior Intercostal Plane Block for Pain Control After MastectomyNCT07929090 · Not applicable · Bursa City Hospital · starts Nov 1, 2026
- A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsNCT07923214 · Phase 1 · Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · starts Jul 2, 2024
- A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation…NCT07918989 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Oct 30, 2026
- Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery…NCT07920094 · Not applicable · Sir Run Run Shaw Hospital · starts Jul 1, 2023
Approved 24 of 48
- CapecitabineThymidylate synthase inhibitor
- DocetaxelTubulin inhibitor
- PaclitaxelTubulin inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- LetrozoleCytochrome P450 19A1 inhibitor
- FulvestrantEstrogen receptor alpha antagonist
- CyclophosphamideDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- AnastrozoleCytochrome P450 19A1 inhibitor
- PertuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- ExemestaneCytochrome P450 19A1 inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- EpirubicinDNA inhibitor
- PalbociclibCDK6/cyclin D1 inhibitor
- TamoxifenEstrogen receptor alpha modulator
- LapatinibReceptor protein-tyrosine kinase erbB-2 inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- Trastuzumab emtansineReceptor protein-tyrosine kinase erbB-2 binding agent
- RibociclibCyclin-dependent kinase 4 inhibitor
- EribulinTubulin inhibitor
- AbemaciclibCyclin-dependent kinase 4 inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- GoserelinGonadotropin-releasing hormone receptor agonist
Phase 3 12 of 150
- CarboplatinDNA inhibitor
- FluorouracilThymidylate synthase inhibitor
- VinorelbineTubulin inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- PyrotinibEpidermal growth factor receptor erbB1 inhibitor
- CisplatinDNA inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
- Dalpiciclib
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
- ThiotepaDNA inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
Phase 2 12 of 399
- DasatinibTyrosine-protein kinase ABL inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- OxaliplatinDNA inhibitor
- ErlotinibEpidermal growth factor receptor erbB1 inhibitor
- PemetrexedThymidylate synthase inhibitor
- TemozolomideDNA inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- CatequentinibVascular endothelial growth factor receptor 2 inhibitor
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- AdebrelimabProgrammed cell death 1 ligand 1 inhibitor
- Leucovorin
Phase 1 or earlier 12 of 208
- Incomplete freund's adjuvant
- OnapristoneProgesterone receptor antagonist
- AlvocidibCyclin-dependent kinase 2 inhibitor
- Hiltonol
- Palazestrant
- Interferon alfa-2bInterferon alpha/beta receptor agonist
- IohexolDiagnostic agent
- PilaralisibPI3-kinase class I inhibitor
- VoxtalisibSerine/threonine-protein kinase mTOR inhibitor
- CapmatinibHepatocyte growth factor receptor inhibitor
- RintatolimodToll-like receptor 3 agonist
- Talimogene laherparepvecMelanoma cell disrupting agent
How its trials ended
11,325 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 2,474 whose ending is known, 34% met their primary endpoint, 8% missed it and 57% stopped early.
- Completed, result not reported4,13937%
- Ongoing3,20328%
- Status unknown1,50913%
- Met its primary endpoint8518%
- Stopped: other or unclear6896%
- Stopped: enrollment or feasibility3963%
- Missed its primary endpoint2102%
- Stopped: sponsor or business decision1511%
- Stopped: lack of efficacy901%
- Stopped: funding651%
- Stopped: safety22<1%
| Oct 21, 2026 | A global, interventional, open-label trial of t-dxd-based therapy followed by palbociclib, endocrine therapy and dual HER2 blockade in first-line HER2+/HR+…Enhertu / Arimidex / Aromasin / Faslodex / Femara / Ibrance / Perjeta / Herzuma… | Daiichi Sankyo | Pending |
| Oct 15, 2026 | An open-label randomized phase 2 study to evaluate safety and efficacy of patritumab deruxtecan plus pembrolizumab administered either before or after…Patritumab deruxtecan (MK-1022) / Pembrolizumab (MK-3475) | Merck & Co. (MSD) | Pending |
| Aug 31, 2026 | A phase IIIb, single-arm, open-label, multicenter study evaluating the treatment adherence, tolerability, and patient-reported outcomes of giredestrant in…Giredestrant (GDC-9545, RO7197597) / Leuprolide / Triptorelin | Roche | Ongoing |
| Jul 27, 2026 | Shorter anthracycline-free chemo immunotherapy adapted to pathological response in early triple negative breast cancer (SCARLET), a randomized phase III studyCarboplatin / Pembrolizumab (keytruda) | BC Cancer, Part of The Provincial Health Services Authority | Pending |
| Jun 9, 2026 | An open label, multi-center alpelisib roll-over study to assess long-term safety in participants who have completed a novartis sponsored alpelisib (BYL719)…Alpelisib (BYL719) / Fulvestrant | Novartis Pharmaceuticals | Pending |
| Jun 5, 2026 | An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor…IEV407 / Fulvestrant / Letrozole | Novartis Pharmaceuticals | Ongoing |
| May 6, 2026 | An open-label, multi-center, phase I/II study of ERW316 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and…ERW316 / Fulvestrant / Letrozole | Novartis Pharmaceuticals | Closed |
| Feb 13, 2026 | A phase 2, randomized, open-label dose optimization and phase 3, randomized, double-blind, placebo-controlled study of tersolisib (LY4064809) combined with a…Tersolisib (LY4064809, STX-478) / Abemaciclib / Ribociclib / Palbociclib /… | Eli Lilly | Pending |
| Feb 2, 2026 | A two-part, seamless, multicenter, randomized, open-label, adaptive phase II/III study of the blood-brain barrier penetrant RO7771950 versus tucatinib, both in…RO7771950 (ZN-A-1041) / Tucatinib / Trastuzumab (RO0452317) / Capecitabine | Roche | Ongoing |
| Dec 17, 2025 | Rebooting sensitivity to checkpoint blockade therapy in triple-negative breast cancer with isunakinra (resett- i)Isunakinra | University Health Network | Ongoing |
| Oct 7, 2026 | TukysaIn combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or… | Seattle Genetics, Inc. | Approved |
| Apr 17, 2020 | TucatinibTUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or… | Seattle Genetics, Inc. | Approved |
| Sep 13, 2007 | EvistaReduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in… | Eli Lilly and Company | Approved |
| Oct 21, 1999 | AromasinTreatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. | Pharmacia & Upjohn | Approved |
| Sep 15, 1999 | EllenceComponent of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. | Pharmacia & Upjohn Company | Approved |
| May 29, 1997 | FarestonTreatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors. | Orion Corporation | Approved |
| May 26, 1995 | ZinecardCardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of… | Pharmacia & Upjohn | Approved |
| Nov 20, 2024 | AzeliragonTreatment of breast cancer brain metastases | Cantex Pharmaceuticals | Designated |
| Mar 21, 2024 | UtideloneTreatment of breast cancer brain metastases | Biostar Pharma, Inc. | Designated |
| Nov 2, 2023 | BMEDA-chelated Rhenium-186 nanoliposomesTreatment of breast cancer with leptomeningeal metastases (LM) | Plus Therapeutics, Inc. | Designated |
| Feb 28, 2017 | (s)-perillyl alcohol temozolomide carbamateTreatment of intracranially located metastases from breast cancer | NeOnc Technologies, Inc. | Designated |
| Apr 15, 2015 | [α′N-(2′succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg…Treatment of breast cancer patients with brain metastases | Angiochem, Inc. | Designated |
| Jul 28, 2004 | EfaproxiralAdjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer | Allos Therapeutics, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA